Skip to main content
ChemoPrescribe LLC.
  • HOME
  • ABOUT
  • SIGN IN
  • SIGN UP

Other Pages – Top Ad

Oncoprescribe-SI

Advertisement

⟰ 🠈

CALQUENCE® (Acalabrutinib)

November 29, 2019April 5, 2020 RR FDA Approvals
Chronic Lymphocytic Leukemia

The FDA on November 21, 2019 approved CALQUENCE® for adults with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). CALQUENCE® is a product of AstraZeneca.

Related Posts:

  • CALQUENCE® (Acalabrutinib)
  • CALQUENCE® May Be Safer Than IMBRUVICA® in…
  • FDA Approves CALQUENCE® for Chronic Lymphocytic Leukemia
  • FDA Grants Approval to CALQUENCE® for Mantle…

Post navigation

OXBRYTA® (Voxelotor)
GIVLAARI® (Givosiran)

Other Pages – Bottom Ad

hem-onc-updates

Advertisement

Subscribe

FREE SUBSCRIPTION
  • ABOUT
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
ChemoPrescribe LLC. All Rights Reserved

Leaving ChemoPrescribe

You are now leaving ChemoPrescribe website.

To return to the website, click on the back arrow on your browser.